Abstract: Age-related macular degeneration (AMD) is a leading cause for severe visual loss and legal blindness in seniors worldwide. The molecular basis for the disease remains poorly understood, likely involving genetic and environment-related ocular defects. Its pathogenesis proceeds slowly, started with deposits of fatty proteins (drusen) in the Bruch’s membrane, followed by gradual impairments of the posterior choriocapillaris and the anterior retinal pigment epithelium (RPE), and lead to irreversible degeneration of the light receiving neurons (photoreceptor) and vision decline. Clinically, AMD is divided into two subgroups: dry or atrophy form and wet or exudative form. Twenty percent of AMD patients have the wet form. The wet AMD is linked to choroidal neovascularization  located in the subretinal macular region, with subsequent bleeding, and a possible sudden loss of central vision. AMD is an incurable devastating disease though the wet form is treatable by anti-vascular endothelial growth factor (VEGF) drugs to inhibit choroidal neovascularization so as to improve or maintain patients’ visual function. For the dry form of AMD unfortunately, there is no effective treatment available in the clinic though the light at the end of tunnel is emerging: cell-based therapy is a potential solution for treating AMD (Chichagova et al., 2018).